Short communication: Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy

AIDS Research and Human Retroviruses

Volumn 23, Issue 9, 2007, Pages 1078-1082

  Poveda, Eva ^a   Briz, Veronica ^a   Paraskevis, Dimitrios ^b   Barreiro, Pablo ^a   Hatzakis, Angelos ^b   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 41; PROTEINASE INHIBITOR; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT; VIRUS DNA; VIRUS RNA;

ARTICLE; BLOOD CELL; CELL COMPARTMENTALIZATION; CLINICAL ARTICLE; DRUG EXPOSURE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LONGITUDINAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS REPLICATION; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; BLOOD; CHEMISTRY; DNA SEQUENCE; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR GENETICS; MONONUCLEAR CELL; MUTATION; SALVAGE THERAPY; VIROLOGY;

AMINO ACID SEQUENCE; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; RNA, VIRAL; SALVAGE THERAPY; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE;

EID: 35348891666     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0287     Document Type: Article

References (16)

1. Poveda E, Briz V, and Soriano V: Enfuvirtide, an HIV-1 fusion inhibitor to treat HIV infection. AIDS Rev 2005;7:139-147.
2. Wei X, Decker J, Liu H, Zhang Z, Arani K, Kilby J, et al.: Emergence of resistant HIV-1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46:1896-1905.
3. Sista P, Melby T, Davison D, Mosier S, Mink M, Nelson E, et al.: Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004;18:1787-1794.
4. Poveda E, Rodés B, Labernardière JL, Benito JM, Toro C, Gonzalez-Lahoz J, et al.: Evolution of genotypic and phenotypic resistance to enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol 2004;74:21-28.
5. Aquaro S, D'Arrigo R, Svicher V, Perri GD, Caputo S, Visco-Comandini U, et al.: Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1 infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 2006;58:714-722.
6. Poveda E, Rodés B, Lebel-Binay S, Faudon JL, Jimenez V, and Soriano V: Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. J Clin Virol 2005;34:295-301.
7. Melby T, Sista P, DeMasi R, Roberts N, Salgo M, Heilek-Snyder G, et al.: Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses 2006;22:375-385.
8. Poveda E, Briz V, Lebel-Binay S, Faudon J, Leal M, and Soriano V: Phenotypic impact of genetic changes selected within HR1/HR2 gp41 domains in HIV-infected patients on long-term enfuvirtide therapy and following drug discontinuation. Presented at the 4th European HIV Drug Resistance Workshop, Monte Carlo, 2006. Abstract 35.
9. Swofford DL: PAUP*: Phylogenetic Analysis Using Parsimony (*and Other Methods), version 4.0b. Sinauer Associates, Sunderland, MA, 2003.
10. Xu L, Pozniak A, Wildfire A, Stanfield-Oakley S, Mosier S, Ratcliffe D, et al.: Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 2005;49:1113-1119.
11. Ruff C, Ray S, Known P, Zinn R, Pendleton A, Hutton N, et al.: Persistence of wild-type and lack of temporal structure in the latent reservoir for HIV type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 2002;76:9481-9492.
12. Simmonds P, Zhang L, McOmish F, Balfe P, Ludlam C, and Brown A: Discontinuous sequence change of HIV type 1 Env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: Implications for models of HIV pathogenesis. J Virol 1991;65:6266-6276.
13. Fulcher J, Hwangbo Y, Zioni R, Nickle D, Lin X, Heath L, et al.: Compartmentalization of HIV type 1 between blood monocytes and CD4+ T cells during infection. J Virol 2004;78:7883-7893.
14. Paolucci S, Baldanti F, Campanini G, Zavattoni M, Cattaneo E, Dossena L, et al.: Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients. J Med Virol 2001;65:207-217.
15. Wang Y, Dyer W, Workman C, Wang B, Sullivan J, and Saksena N: Molecular evidence for drug-induced compartmentalization of HIV-1 quasispecies in a patient with periodic changes to HAART. AIDS 2000;14:2265-2272.
16. Potter S, Dwyer D, and Saksena N: Differential cellular distribution of HIV-1 drug resistance in vivo: Evidence for infection of CD8+ T cells during HAART. Virology 2003;305:339-352.